1
|
Lee WS, Kim JY, Won HJ, Lee SM, Suh YS, Joo YD, Lee JY, Jang WH, Kang SW, Kang MS, Park SG, Choi IW, Choi I, Seo SK. Effect of upregulated TLR2 expression from G-CSF-mobilized donor grafts on acute graft-versus-host disease. Int Immunopharmacol 2015; 29:488-493. [PMID: 26462591 DOI: 10.1016/j.intimp.2015.10.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2015] [Revised: 09/16/2015] [Accepted: 10/05/2015] [Indexed: 11/30/2022]
Abstract
Our previous study demonstrated that G-CSF treatment increased the expression of TLR2 in donor grafts; this contributed to rapid engraftment after allogeneic hematopoietic stem cell transplantation (HSCT) in mice. In the current study, we investigated the effects of upregulated TLR2 expression in G-CSF-mobilized donor grafts on acute graft-versus-host disease (GVHD). We found that TLR2 was highly expressed on myeloid cell populations but not T and B cells from the spleens of G-CSF-treated donor mice. After transplantation, the mortality and disease severity in recipients were not significantly different between G-CSF-treated TLR2-/- and wt donor grafts. Although endogenous TLR2 ligand was detected in the serum of both recipients, T cells from TLR2-/- and wt donors have the same ability regarding alloreactivity. Moreover, the blockade of TLR2 signaling in recipients by administering anti-TLR2 blocking antibody after BMT did not lead to a significant difference in acute GVHD compared with control IgG treatment. However, the hematopoietic ability of G-CSF-mobilized lin−c-kit+ HSCs from TLR2-/- donor grafts was lower than that from wt donor grafts. Our results demonstrate that upregulated TLR2 expression in G-CSF-mobilized donor grafts has no effect on acute GVHD, suggesting that TLR2 is a valuable target for increasing HSCT efficiency in order to enhance engraftment without exacerbating acute GVHD.
Collapse
Affiliation(s)
- Won-Sik Lee
- Department of Hemato/Oncology, Busan Paik Hospital, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Joo-Yong Kim
- Department of Orthopedic Surgery, Busan Paik Hospital, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Hae-Jeong Won
- Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Soung-Min Lee
- Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Young-Sill Suh
- Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Young-Don Joo
- Department of Hemato/Oncology, Haeundae Paik Hospital, College of Medicine, Inje University, Busan 612-030, South Korea
| | - Ji-Young Lee
- Department of Hemato/Oncology, Busan Paik Hospital, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Won-Hee Jang
- Department of Biochemistry, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Sun-Woo Kang
- Department of Nephrology, Busan Paik Hospital, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Mi-Sun Kang
- Department of Pathology, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Sae-Gwang Park
- Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Il-Whan Choi
- Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Inhak Choi
- Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 614-735, South Korea
| | - Su-Kil Seo
- Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 614-735, South Korea.
| |
Collapse
|